title: Patients with advanced and metastatic renal cell carcinoma treated with targeted therapy in the Czech Republic: twenty cancer centres, six agents, one database.
abstract: The incidence and mortality of renal cell carcinoma (RCC) in the Czech Republic are among the highest in the world. Several targeted agents have been recently approved for the treatment of advanced/metastatic RCC.
  
  
  OBJECTIVE
  Presentation of a national clinical database for monitoring and assessment of patients with advanced/metastatic RCC treated with targeted therapy. The RenIS (RENal Information System, http://renis.registry.cz ) registry is a non-interventional post-registration database of epidemiological and clinical data of patients with RCC treated with targeted therapies in the Czech Republic. Twenty cancer centres eligible for targeted therapy administration participate in the project. As of November 2011, six agents were approved and reimbursed from public health insurance, including bevacizumab, everolimus, pazopanib, sorafenib, sunitinib, and temsirolimus. As of 10 October 2011, 1,541 patients with valid records were entered into the database. Comparison with population-based data from the Czech National Cancer Registry revealed that RCC patients treated with targeted therapy are significantly younger (median age at diagnosis 59 vs. 66 years). Most RenIS registry patients were treated with sorafenib and sunitinib, many patients sequentially with both agents. Over 10 % of patients were also treated with everolimus in the second or third line. Progression-free survival times achieved were comparable to phase III clinical trials. The RenIS registry has become an important tool and source of information for the management of cancer care and clinical practice, providing comprehensive data on monitoring and assessment of RCC targeted therapy on a national level.
authors: Department of Complex Oncology Care, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53, Brno, Czech Republic.
authors: Alexandr
authors: A
authors: Poprach
authors: Zbyněk
authors: Z
authors: Bortlíček
authors: Tomáš
authors: T
authors: Büchler
authors: Bohuslav
authors: B
authors: Melichar
authors: Radek
authors: R
authors: Lakomý
authors: Rostislav
authors: R
authors: Vyzula
authors: Petr
authors: P
authors: Brabec
authors: Marek
authors: M
authors: Svoboda
authors: Ladislav
authors: L
authors: Dušek
authors: Jakub
authors: J
authors: Gregor
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D018153:Czech Republic / Q000453:epidemiology; D016208:Databases, Factual; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D058990:Molecular Targeted Therapy; D012042:Registries
chemical_list: D000970:Antineoplastic Agents